Tara Masterson
Johnson & Johnson (United States)(US)Springhouse(US)Janssen (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Monoclonal and Polyclonal Antibodies Research, Peptidase Inhibition and Analysis, Protein Degradation and Inhibitors, HER2/EGFR in Cancer Research
Most-Cited Works
- → Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial(2020)233 cited
- → Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma(2019)115 cited
- → EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma(2024)97 cited
- → GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review(2024)87 cited
- → Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).(2023)86 cited
- → Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy(2015)68 cited